ReviewBiosafety and health2023
Advances in treatment strategies for COVID-19: Insights from other coronavirus diseases and prospects.
Review in Biosafety and health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The first key for the Priority Pathogens: Protective immunogens in development of vaccines and medications.Biosafety and health · 2026Review
- Computational discovery of SARS-CoV-2 viral entry inhibitory peptides fromFrontiers in bioinformatics · 2026Article
- Article
- Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis.Biosafety and health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is the third human disease outbreak caused by an emerging coronavirus in the 21st century. Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the COVID-19 pandemic has been the most devastating, with millions of deaths. Medical countermeasures are needed to limit the number of infections and fatalities. Here, we discuss advances in clinical and research-based treatment methods for SARS-CoV-2 that were initially derived from treatments for other coronaviruses. Recent advances in SARS-CoV-2 treatments, from traditional drugs and immunotherapies to artificial intelligence to predict potential future treatment methods, are summarized and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.